Access cutting-edge colorectal cancer treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.
Access colorectal cancer specialists in Chicago at no cost
This study follows strict safety protocols and ethical guidelines
All study-related colorectal cancer treatment provided free
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care (SOC) given alone. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of CRC. This study will be divided into two groups called treatment arms. In arm 1 participants will receive telisotuzumab adizutecan alone. In arm 2 participants will r
Sponsor: AbbVie
Check if you qualify for this colorectal cancer clinical trial in Chicago, IL
If you're searching for colorectal cancer treatment options in Chicago, IL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced colorectal cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.